Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Furosemide Tablets (20mg), a type 3 chemical drug. This development is significant for the company as it enhances their product portfolio in treating conditions such as edema, hypertension, and acute kidney failure, potentially strengthening their market position and offering new opportunities for growth.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in creating medications for various health conditions, with a market focus on enhancing drug consistency and efficacy.
YTD Price Performance: -20.41%
Average Trading Volume: 13,076,849
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.12B
See more data about 2005 stock on TipRanks’ Stock Analysis page.